<DOC>
	<DOCNO>NCT01275222</DOCNO>
	<brief_summary>This trial Phase I/II , non-randomized , open label , multi-center study , follow sequential 2- part design . The first part , Phase I , design ass whether pharmacokinetic interaction Glivec/Gleevec ( imatinib ) RAD001 ( everolimus ) well collect safety data two drug co-administered . The second part , ( Phase II ) , design ass potential efficacy combination imatinib-resistant GIST patient two strata patient : - Patients resistant imatinib first-line drug therapy maximum tolerate dose least 600 mg/d ( Stratum 1 , first-line resistant/refractory ) - Patients resistant imatinib well post-imatinib drug therapy ( Stratum 2 , post second-line therapy ) .</brief_summary>
	<brief_title>Everolimus Combination With Imatinib Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Phase l : Patients age ≥ 18 year Patients histologically proven diagnosis GIST clinical evidence resistance imatinib despite least 4 month continuous treatment imatinib Patients least 2 month dosage ≥ 600 mg/day ( progression despite uninterrupted therapy 2 month ≥800 mg/d patient enter Phase I cohort investigate 800 mg/d dose ) Patients least one measurable lesion ( long diameter ≥20 mm conventional CT MRI scan patient ≥10 mm spiral CT ) WHO Performance Status Score ≤ 2 . Patients also adequate bone marrow , liver renal function imatinib treatment , specify protocol Phase : • For Phase II ( Stratum 2 ) patient must progression 2nd line drug therapy follow prior progression imatinib ( Stratum 2 ) Women pregnant breastfeeding Patients present know symptomatic CNS metastasis leptomeningeal involvement Patients concurrent major medical condition liable compromise patient 's participation study ( e.g . know HIV infection , uncontrolled diabetes , serious cardiac dysrhythmia condition , New York Heart Association classification III IV , congestive cardiac failure , myocardial infarction 6 month , unstable angina , chronic acute renal liver disease , uncontrolled infection include abscess fistula , etc . ) Patients history another malignancy within 5 year prior study entry , except curatively treat nonmelanotic skin cancer insitu cervical cancer Patients unwilling unable comply protocol Patients receive glucocorticoid ( p70s6 kinase1 assay perform ) , since show inhibit p70s6 kinase1 activity . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>GIST</keyword>
	<keyword>everolimus</keyword>
	<keyword>mTOR</keyword>
	<keyword>Imatinib resistant</keyword>
	<keyword>Imatinib-refractory/resistant gastrointestinal stromal tumor</keyword>
</DOC>